JUPITER NEUROSCIENCES, INC. (JUNS) Form 8-K — Jul 21, 2026
$JUNSForm 8-KItems 1.01, 3.02, 9.01Filed Jul 21, 2026, 4:05 PM ET0001493152-26-034077Original filing
Jupiter Neurosciences entered into a definitive Strategic Asset License Agreement with PharmAla Biotech Holdings Inc. to secure exclusive U.S. rights to ALA-002, an investigational compound for neuroinflammation and CNS disorders. The agreement supersedes a prior non-binding term sheet and grants Jupiter a royalty-bearing license to develop, manufacture, and commercialize products incorporating ALA-002 in the United States.
Key figures
- Royalty Rate
- 3%
- Upfront Payment
- $3,333,333
- Upfront Cash Consideration
- $1,500,000
- Commercial Milestones Total
- $73,333,333
- Development Milestones Total
- $23,333,333
- Upfront Equity Consideration
- $1,833,333
Price after filing
1 day: -98.7%7 days: -35.4%30 days: -59.4%
Close on the filing date to close N calendar days later (from $12.73). Historical, not a forecast.
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.